Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.


ER+/HER2+ Metastatic Breast Cancer

October 2nd 2017

Future Directions: CDK4/6 Inhibitors in Breast Cancer

October 2nd 2017

Treatment Selection for HR+ mBC

October 2nd 2017

mBC: CDK4/6 Inhibitor Patient Selection/Sequencing

October 2nd 2017

CDK4/6 Inhibitors in Breast Cancer: Ongoing Research

October 2nd 2017

FDA Approval for Abemaciclib

October 2nd 2017

MONARCH 3: Abemaciclib With Endocrine Therapy for mBC

October 2nd 2017

MONARCH 1: Abemaciclib Monotherapy for HR+ mBC

October 2nd 2017

Abemaciclib + Fulvestrant at Progression of HR+ mBC

October 2nd 2017

Abemaciclib for ER+ mBC

October 2nd 2017

CDK4/6 Inhibitors: Managing Toxicity in HR+ mBC

October 2nd 2017

Clinical Experience: CDK4/6 Inhibitors in Breast Cancer

October 2nd 2017

CDK 4/6 Inhibitors in Metastatic Breast Cancer

October 2nd 2017

Dr. Hoffman-Censits on Biomarker Development in Urothelial Carcinoma

September 29th 2017

Jean Hoffman-Censits, MD, associate professor of Medical Oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses biomarker development in the field of urothelial carcinoma.

PEGPH20 Offers New Mechanism for Attacking Pancreas Tumors

September 29th 2017

PEGPH20 (pegvorhyaluronidase alfa), a novel formulation of a naturally occuring enzyme, is being investigated as a biomarker-driven treatment for patients with advanced pancreatic cancer.

FDA Approves Reduced Dose of Cabazitaxel for mCRPC

September 18th 2017

The FDA has approved a cabazitaxel (Jevtana) regimen of 20 mg/m2 every 3 weeks in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer.

Expert Discusses Approval of First CAR T-Cell Therapy

September 18th 2017

James L. Ferrara, MD, discusses the significance of the FDA approving tisagenlecleucel as the first CAR T-cell therapy.

Emerging Approaches in Liver Cancer

September 8th 2017

Biomarkers in Liver Cancer

September 8th 2017

Immunotherapy in Liver Cancer

September 8th 2017